# CMMB · DEFM14A

- Kind: Filing note
- Ticker: CMMB
- Company: Chemomab Therapeutics Ltd.
- Form: DEFM14A
- Filed: 2026-10-30
- Accession: 0001493152-26-049444
- Canonical: https://edgartracker.com/s/CMMB/2026-10-30/tDsaNyDPgW6exGFuBYsxsw
- Updated: 2026-10-31T02:54:21.139641Z

---

# Chemomab: Merger with Scipher Hinges on $30M–$50M PIPE

Chemomab Therapeutics' recent DEFM14A filing outlines a critical merger with Scipher Medicine, contingent on securing a $30 million to $50 million PIPE financing. This merger represents a strategic pivot, with Scipher taking the lead in operations and governance. Chemomab shareholders face significant dilution, owning just 26.7% of the combined entity post-PIPE, while Scipher noteholders would control 56.7%.

## Ownership and Valuation Dynamics

The merger assigns Chemomab a $48 million valuation and Scipher $102 million, adjusted for Scipher's debt. Initially, Chemomab holders would own 32% of the new company, but this drops to 26.7% with a $30 million PIPE. The PIPE investors, receiving warrants, could see their stake rise to 28.6% upon full exercise. This structure highlights the dilution risk for existing Chemomab shareholders, who must weigh the potential upside against reduced ownership.

## Financing and Dilution Risks

The PIPE is not just a formality; it's a closing condition. Scipher has already raised $10 million in pre-closing financing, which counts toward the PIPE but doesn't bring new cash to the table. This financing structure, while necessary, introduces further dilution through warrant coverage. The combined company’s long-term funding needs remain uncertain, as the current cash position does not guarantee future financial stability.

## Strategic Shift and Execution Risks

Control will shift to Scipher, which plans to leverage its precision-medicine capabilities to explore new avenues, such as testing nebokitug in rheumatoid arthritis. However, this drug has not been tested in humans, making this a high-risk venture. Chemomab’s PSC program retains potential upside through contingent value rights (CVRs), but these are not guaranteed and depend on achieving specific milestones.

## What to Watch

| Catalyst | Why It Matters | Timeline |
|----------|----------------|----------|
| December 4, 2026 | Shareholder meeting on merger and PIPE | Critical vote |
| PIPE Financing | Minimum $30 million needed | Q4 2026 |
| Final Capitalization | Determines ownership and dilution | Post-closing |
| Outside Date | Termination possible if not closed | March 31, 2027 |
| RA Trial | Key development for nebokitug | Post-close |

The merger's success hinges on securing the PIPE financing and meeting various closing conditions. Shareholders must consider the potential for dilution and the strategic shift towards Scipher's unproven RA program.

[Generated on Edgar Tracker · edgartracker.com · Article · GPT 4o]